Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:00 pm Purchase | 2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | TANG CAPITAL MANAGEMENT, LLC | 4,321,547 9.990% | 4,321,547 (New Position) | Filing History |
| 2024-11-14 3:57 pm Purchase | 2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | SUVRETTA CAPITAL MANAGEMENT, LLC | 4,328,904 9.990% | 1,644,899 (+61.29%) | Filing History |
| 2024-11-14 12:02 pm Purchase | 2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | Vestal Point Capital LP | 4,000,000 9.300% | 4,000,000 (New Position) | Filing History |
| 2024-11-13 12:54 pm Purchase | 2024-11-07 | 13G | KalVista Pharmaceuticals, Inc. KALV | Capital World Investors | 3,374,064 7.800% | 3,374,064 (New Position) | Filing History |
| 2024-11-12 4:05 pm Unchanged | 2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | The Vanguard Group | 2,150,527 4.970% | 0 (Unchanged) | Filing History |
| 2024-11-12 09:31 am Purchase | 2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | Adage Capital Management L.P. | 1,419,792 3.290% | 1,419,792 (New Position) | Filing History |
| 2024-11-07 2:34 pm Purchase | 2024-11-05 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 4,887,867 10.000% | 1,200,000 (+32.54%) | Filing History |
| 2024-11-04 12:00 pm Purchase | 2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | The Vanguard Group | 2,150,527 4.970% | 369,108 (+20.72%) | Filing History |
| 2024-04-01 4:14 pm Sale | 2024-03-28 | 13D | KalVista Pharmaceuticals, Inc. KALV | TCG Crossover GP I LLC | 1,345,826 3.200% | -1,355,014 (-50.17%) | Filing History |
| 2024-02-26 4:35 pm Purchase | 2024-02-15 | 13G | KalVista Pharmaceuticals, Inc. KALV | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,845,000 6.870% | 2,845,000 (New Position) | Filing History |
| 2024-02-22 1:22 pm Purchase | 2024-02-20 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 3,687,867 8.900% | 105,573 (+2.95%) | Filing History |
| 2024-02-20 4:49 pm Sale | 2024-02-07 | 13D | KalVista Pharmaceuticals, Inc. KALV | TCG Crossover GP I LLC | 2,700,840 6.520% | -707,241 (-20.75%) | Filing History |
| 2024-02-14 8:52 pm Purchase | 2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | Venrock Healthcare Capital Partners III L.P. | 4,824,731 14.000% | 1,251,017 (+35.01%) | Filing History |
| 2024-02-14 4:00 pm Purchase | 2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | TANG CAPITAL PARTNERS LP | 3,440,345 9.960% | 243,899 (+7.63%) | Filing History |
| 2024-02-13 5:19 pm Purchase | 2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | SUVRETTA CAPITAL MANAGEMENT, LLC | 2,684,005 7.800% | 887,626 (+49.41%) | Filing History |
| 2024-02-13 5:07 pm Purchase | 2023-12-29 | 13G | KalVista Pharmaceuticals, Inc. KALV | The Vanguard Group | 1,781,419 5.150% | 1,781,419 (New Position) | Filing History |
| 2024-02-12 8:30 pm Purchase | 2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | Saturn V Capital Management LP | 1,431,259 4.100% | 1,431,259 (New Position) | Filing History |
| 2024-02-09 09:16 am Sale | 2024-02-08 | 13G | KalVista Pharmaceuticals, Inc. KALV | FMR LLC | 50,970 0.147% | -1,260,032 (-96.11%) | Filing History |
| 2024-01-29 3:26 pm Purchase | 2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | BlackRock Inc. BLK | 2,242,025 6.500% | 669,604 (+42.58%) | Filing History |
| 2023-12-28 4:16 pm Purchase | 2023-12-26 | 13G | KalVista Pharmaceuticals, Inc. KALV | Venrock Healthcare Capital Partners III L.P. | 3,573,714 10.300% | 657,047 (+22.53%) | Filing History |